Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and Risk Factors
-
1. Coronary heart disease epidemiology: global context for a new genetic understanding
- Prof. Harry Hemingway
-
2. Cardiovascular risk factors
- Dr. Michal Vrablik
-
3. Lipoproteins
- Prof. Arnold von Eckardstein
-
4. Thrombotic risk factors for cardiovascular disease
- Prof. Gordon Lowe
-
5. Lipoprotein(a)
- Dr. Jaimini Cegla
- Biology of Coronary Heart Disease
-
6. Plaque rupture
- Prof. Petri Kovanen
-
7. Transcription factors and complex disease development
- Dr. Ines Pineda-Torra
-
8. Animal models to explore cardiovascular disease
- Prof. Martin Merkel
- Treatment
-
9. Diagnosis and treatment of dyslipidemias
- Prof. Anton Stalenhoef
-
10. Key drug discovery challenges in cardiovascular medicine
- Dr. Dan Swerdlow
- Dr. Michael V. Holmes
- Genetics
-
11. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
12. Heart disease genes and SNPs
- Prof. Steve Humphries
-
13. Familial hypercholesterolaemia: genetic causes and treatment
- Prof. Steve Humphries
-
14. Familial hypercholesterolaemia: cascade testing and monogenic vs. polygenic causes
- Prof. Steve Humphries
-
16. Genetics of cardiovascular disease
- Prof. Philippa Talmud
-
17. The genetics of CHD: moving research findings into patient benefit
- Prof. Steve Humphries
-
19. The genetics of abdominal aortic aneurysm
- Dr. Seamus Harrison
-
20. Genome scans for hypertension
- Prof. Patricia Munroe
-
21. Telomeres and cardiovascular disease
- Dr. Jess Buxton
-
23. Genetics of hypertrophic cardiomyopathy (HCM)
- Dr. Petros Syrris
- Archived Lectures *These may not cover the latest advances in the field
-
24. Gene-environment interaction and oxidative stress in cardiovascular disease
- Dr. Jeffrey Stephens
-
25. Gene therapy as a therapeutic option for lipoprotein lipase deficiency
- Dr. Jan Albert Kuivenhoven
-
26. Cardiovascular diseases: from epidemiology to nutritional interventions
- Dr. Antonis Zampelas
-
27. Genetic testing for CHD risk: fact or fiction?
- Prof. Steve Humphries
-
28. Pharmacogenetics: progress, pitfalls and clinical potential
- Prof. Steve Humphries
-
29. Familial hyperchlolesterolaemia: a monogenic cause of early CHD
- Prof. Steve Humphries
-
30. Lipid metabolism
- Dr. Ulrike Beisiegel
Printable Handouts
Navigable Slide Index
- Introduction
- Cardiovascular risk and risk factors
- Different risk categories
- CVD - leading cause of adult mortality worldwide
- Leading causes of death, Canada, 1998
- CVD mortality, USA, 1980-2003
- Standardized mortality- Czech Rep., 1990-2006
- Global burden of cardiovascular disease
- The EUROASPIRE III study
- Atherogenesis
- Atherosclerosis
- Clinical manifestations of atherosclerosis
- Risk factors
- Risk factors for cardiovascular disease
- Modifiable vs. non-modifiable risk factors
- The risk is multiplicative
- Combination of risk factors increases risk of MI
- Non-modifiable risk factors
- Modifiable risk factors
- Dyslipidemia as a significant risk factor for CVD
- Structure of lipoproteins
- Classification of dyslipidaemias
- Types of lipoprotein particles
- Relationship between cholesterol and CHD risk
- Relationship of serum cholesterol to mortality
- LDL cholesterol
- Relationship between LDL-C and CV event rate
- Prevalence of raised LDL cholesterol
- HDL cholesterol
- Triglycerides
- Triglyceride levels and LDL phenotypes
- Impact of TG levels on relative risk (RR) of CHD
- Apolipoproteins
- The INTERHEART study
- Risk of AMI associated with risk factors
- Risk factors and risk of MI
- ApoB/ApoA-I as a predictor of risk
- INTERHEART study conclusion
- Indicators of plasma atherogenic phenotype
- CAD risk and HDL particle size
- HDL protective and risk particles
- CAD risk and LDL particle size
- Subfrakce LDL
- CAD risk and VLDL particle size
- TG and HDL-C levels determine LP particle size
- Smoking as a risk factor for CVD
- Smoking and mortality
- Cumulative tobacco related death rate worldwide
- Smoking and MI risk
- CHD risk and smoking: dose dependence
- Passive smoking risk
- Smoking and atherogenesis
- Adverse effect of smoking on different risk factors
- Endothelium damage after smoke exposure
- Prevalence of smoking
- Diabetes as a risk factor for CVD
- Diabetes mellitus
- Estimates of incident of type II diabetes
- Types of diabetes mellitus
- The chronic complications of diabetes mellitus
- Typical lipid profile in patients with/without DM
- Diabetics at similar risk to non diabetics with CVD
- Less favourable angioplasty outcome in diabetes
- Diabetic resistance to CVD preventive strategies
- Prevalence of diabetes
- The metabolic syndrome
- The MetS and associated CVD risk factors
- Criteria for diagnosis of the metabolic syndrome
- Prevalence of MetS in the USA
- MetS and CVD
- Higher rates of atherosclerosis in MetS patients
- Overweight and obesity as a risk factor
- Prevalence of obesity
- Survival of the fittest
- How to assess the risk?
- Risk assessment
- Why do we assess risk?
- The SCORE chart
- Framingham point score
- Atherosclerosis imaging (1)
- Atherosclerosis imaging (2)
- Intima media thickness (IMT)
- IMT and CV events
- Carotid IMT measurement
- IMT of carotid arteries
- Normal finding on carotid US
- Pathological finding
- Carotid IMT is a measure of atherosclerosis
- Example of atherosclerosis regression, IVUS
- CT angiography
- Conclusions
Topics Covered
- Cardiovascular disease burden
- Atherosclerosis as a cause of CVD
- Non-modifiable and modifiable risk factors for CVD
- Dyslipidemia and CVD risk
- Apoproteins as CVD risk predictors
- Quality of lipoprotein particles as an important indicator of lipids associated risk
- Smoking as a CVD risk factor
- Diabetes as a risk factor for CVD
- Metabolic syndrome and CVD risk
- Risk assessment tools
- Atherosclerosis imaging techniques and risk assessment
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Vrablik, M. (2008, November 24). Cardiovascular risk factors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 21, 2025, from https://doi.org/10.69645/JUMX6928.Export Citation (RIS)
Publication History
- Published on November 24, 2008
Financial Disclosures
- Dr. Michal Vrablik has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.